Colorectal cancer screening increased 12% and breast cancer screening increased 7% between 2019 and 2023. Cervical cancer screening remained 14% below rates from 2019, neither increasing or decreasing ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

Cervical cancer incidence is rising, with rural and minoritized populations experiencing worse outcomes due to suboptimal ...

KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, evaluated under multiple criteria prior to approval' ...

Cervical cancer is the fourth most common cancer among women worldwide. In India, where it is the second most common, it ...

Joining a clinical trial for cervical cancer opens the door to new treatments that could have life-changing effects.

A mom who was diagnosed with stage four cervical cancer claims doctors said her blood clot symptoms were “just your period.” Charley Jayne Law, 31, began bleeding clots the size of her ...

Pembrolizumab is not publicly available at the moment for cervical cancer patients in Ireland and costs in the region of €8,000 per infusion every three weeks. Vicky also travels to Galway for ...